In a patient with delirium and severe agitation and a QTc of 465 ms, is haloperidol combined with lorazepam or haloperidol combined with diphenhydramine the preferred regimen for agitation?

Haloperidol + Lorazepam is the Preferred Regimen

In a patient with severe agitation from delirium and a QTc of 465 ms, haloperidol combined with lorazepam is preferred over haloperidol combined with diphenhydramine. The combination of haloperidol and lorazepam has the strongest evidence for efficacy in severe agitation, and diphenhydramine itself prolongs QTc and should be avoided in this clinical scenario.

Evidence-Based Rationale

Why Haloperidol + Lorazepam

The combination of haloperidol and lorazepam provides superior sedation compared to either agent alone 1. Guidelines specifically recommend this combination as a Level C recommendation for producing more rapid sedation than monotherapy in acutely agitated psychiatric patients 1.

The most compelling recent evidence comes from:

• Network meta-analysis (2019): Haloperidol plus lorazepam provided the best response rate for delirium treatment (OR 28.13,95% CI 2.38-333.08) compared to placebo 2

• Randomized controlled trial (2017): In 90 patients with advanced cancer and agitated delirium, lorazepam + haloperidol resulted in significantly greater reduction in agitation at 8 hours (-4.1 points vs -2.3 points on RASS, mean difference -1.9, p<0.001) compared to haloperidol alone 3

• Multicenter RCT (1997): The combination treatment produced most rapid tranquilization with significant differences at hour 1 on agitation scales 4

Critical QTc Consideration: Why NOT Diphenhydramine

Diphenhydramine is explicitly listed as a QT-prolonging medication 5. With your patient's baseline QTc already at 465 ms (approaching the concerning threshold of 500 ms), adding diphenhydramine creates additive QT prolongation risk on top of haloperidol's known effects.

The pediatric guidelines specifically warn that diphenhydramine appears on the list of QT-interval-prolonging medications 5. While haloperidol also prolongs QTc, the evidence shows that at therapeutic doses, antipsychotics prolong QTc but rarely exceed 500 ms 1.

Practical Dosing Algorithm

Initial dosing:

• Haloperidol 5 mg IM/IV + Lorazepam 2 mg IM/IV 1, 3, 4

Reassess at 1 hour:

• If inadequate response: Repeat same doses (can give 1-6 doses within 12 hours based on clinical need) 4
• Monitor RASS score hourly

QTc monitoring:

• Obtain baseline ECG (already done: 465 ms)
• Repeat ECG after each dose if QTc >500 ms or if patient develops new arrhythmia symptoms
• Hold further doses if QTc exceeds 500 ms

Important Caveats and Safety Monitoring

Drug Interaction Warning

The FDA label explicitly warns about haloperidol-lorazepam combination risks 6: "Apnea, coma, bradycardia, arrhythmia, heart arrest, and death have been reported with the concomitant use of haloperidol and lorazepam." However, this must be contextualized—these are rare events, and the combination remains widely used and recommended in guidelines 1.

Monitor for:

• Respiratory depression (most common concern with combination therapy) 6
• Hypotension (benzodiazepines carry this risk) 7
• Extrapyramidal symptoms (haloperidol-related, though less common with combination vs haloperidol alone) 4
• Paradoxical disinhibition (rare with benzodiazepines) 5

Dose Adjustments

If patient is on valproate: Reduce lorazepam dose by 50% (valproate decreases lorazepam clearance by 40%) 6

If patient is on probenecid: Reduce lorazepam dose by 50% (prolongs half-life by 130%) 6

If patient is on oral contraceptives: May need to increase lorazepam dose (increases clearance 3.7-fold) 6

Why This Matters for Delirium

Delirium requires rapid control of agitation to prevent harm to patient and staff, while avoiding oversedation that worsens confusion. The haloperidol-lorazepam combination achieves this balance better than alternatives:

• Faster onset than haloperidol alone 3, 4
• Less rescue medication needed (median 2 mg vs 4 mg additional neuroleptics) 3
• Better perceived comfort by caregivers (84% vs 37%) and nurses (77% vs 30%) 3

The 2018 Critical Care guidelines note that while they suggest against routine antipsychotic use for delirium, patients with significant distress, hallucinations, or risk of self-harm may benefit from short-term use until symptoms resolve 8—which describes your severely agitated patient.

Bottom line: Use haloperidol 5 mg + lorazepam 2 mg IM/IV, monitor QTc closely, and avoid diphenhydramine given the already-elevated QTc of 465 ms.